NEW
YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of GSK
plc (NYSE: GSK).
Shareholders who purchased shares of GSK during the class period
listed are encouraged to contact the firm regarding possible lead
plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=128958&from=4
CLASS PERIOD: February 5,
2020 to August 14, 2022
ALLEGATIONS: According to the filed complaint, defendants
represented to investors that GSK removed Zantac from the market
"[b]ased on information available at the time and correspondence
with regulators." GSK also stated that it was "continuing with
investigations into the potential source of NDMA." Defendants also
assured investors that "GSK, the FDA, and the EMA [European
Medicines Agency] have all independently concluded that there is no
evidence of a causal association between ranitidine therapy and the
development of cancer in patients," findings that were "consistent
with other ranitidine data published prior to 2019." Finally,
defendants claimed that they could not "quantify or reliably
estimate the liability." These representations were materially
false or misleading. In truth, GSK was fully aware of the source of
NDMA and had been for nearly 40 years before withdrawing Zantac
from the market.
DEADLINE: April 7, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=128958&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of GSK during the timeframe listed
above, you will be enrolled in a portfolio monitoring software to
provide you with status updates throughout the lifecycle of the
case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to
you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-gsk-plc-gsk-seeking-recovery-for-investors--contact-the-gross-law-firm-302375173.html
SOURCE The Gross Law Firm
